{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:37:17Z","timestamp":1791121037737,"version":"4.1.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2002,8,1]],"date-time":"2002-08-01T00:00:00Z","timestamp":1028160000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2003,12,30]],"date-time":"2003-12-30T00:00:00Z","timestamp":1072742400000},"content-version":"vor","delay-in-days":516,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,8]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Treatment of hepatorenal syndromes (HRSs) is currently based on vasopressin analogs. The aim of this pilot study was to evaluate the efficacy and safety of noradrenalin (NA) in the treatment of type 1 HRS. Between 1998 and 2000, 12 consecutive patients with type 1 HRS (7 men, 5 women; mean age, 54 \u00b1 11 years; mean Child-Pugh score, 11.3 \u00b1 1.7) were treated with intravenous NA (0.5-3 mg\/h), in combination with intravenous albumin and furosemide. NA was given for 10 \u00b1 3 days, at a mean dose of 0.8 \u00b1 0.3 mg\/h. Reversal of HRS was observed in 10 of 12 patients (83%; 95% confidence interval, 52%-98%) after a median of 7 days (range, 5-10 days). Serum creatinine levels fell from 358 \u00b1 161 to 145 \u00b1 78 \u03bcmol\/L (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001), creatinine clearance rose from 13 \u00b1 9 to 40 \u00b1 15 mL\/min (<jats:italic toggle=\"yes\">P<\/jats:italic> = .003), and urinary sodium output increased from 8 \u00b1 14 to 52 \u00b1 72 mEq\/d (<jats:italic toggle=\"yes\">P<\/jats:italic> = .002). Changes in renal function under NA treatment were associated with an increase in mean arterial pressure (MAP; 65 \u00b1 7 to 73 \u00b1 9 mm Hg, <jats:italic toggle=\"yes\">P<\/jats:italic> = .01) and a marked reduction in active renin (565 \u00b1 989 to 164 \u00b1 196 ng\/L, <jats:italic toggle=\"yes\">P<\/jats:italic> = .001) and aldosterone plasma concentrations (1,945 \u00b1 1,931 to 924 \u00b1 730 ng\/mL, <jats:italic toggle=\"yes\">P<\/jats:italic> = .02). There was one episode of reversible myocardial hypokinesia (in a patient on 1.5 mg\/h NA) that did not recur after a dose reduction. In conclusion, NA combined with albumin and furosemide appears effective and safe for the treatment of type 1 HRS.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1053\/jhep.2002.34343","type":"journal-article","created":{"date-parts":[[2003,6,21]],"date-time":"2003-06-21T14:16:51Z","timestamp":1056205011000},"page":"374-380","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":286,"title":["Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: A pilot study"],"prefix":"10.1097","volume":"36","author":[{"given":"Christophe","family":"Duvoux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Zanditenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"H\u00e9zode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Chauvat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Monin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Roudot-Thoraval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Mallat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Dhumeaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1053\/jhep.2002.34343-BIB1|cit1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/hep.510230122","article-title":"International Ascites Club. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis","volume":"23","author":"Arroyo","year":"1996","journal-title":"Hepatology"},{"key":"10.1053\/jhep.2002.34343-BIB2|cit2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0016-5085(93)90031-7","article-title":"Incidence, predictive factor and prognosis of the hepatorenal syndrome in cirrhosis with ascites","volume":"105","author":"Gines","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1053\/jhep.2002.34343-BIB3|cit3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00007890-199502150-00010","article-title":"Impact of pretransplant renal function on survival after liver transplantation","volume":"59","author":"Gonwa","year":"1995","journal-title":"Transplantation"},{"key":"10.1053\/jhep.2002.34343-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/0016-5085(91)90734-3","article-title":"Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis","volume":"101","author":"Lenz","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1053\/jhep.2002.34343-BIB5|cit5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hep.510270107","article-title":"Reversibility of hepatorenal syndrome by prolonged administration of ornipressine and plasma volume expansion","volume":"27","author":"Guevara","year":"1998","journal-title":"Hepatology"},{"key":"10.1053\/jhep.2002.34343-BIB6|cit6","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/hep.510300430","article-title":"Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressine and dopamine","volume":"30","author":"G\u00fclberg","year":"1999","journal-title":"Hepatology"},{"key":"10.1053\/jhep.2002.34343-BIB7|cit7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0168-8278(98)80151-7","article-title":"Beneficial effects of 2-day administration of terlipressine in patients with cirrhosis and hepatorenal syndrome","volume":"29","author":"Hadengue","year":"1998","journal-title":"J Hepatol"},{"key":"10.1053\/jhep.2002.34343-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1007\/BF02088218","article-title":"Hepatorenal syndrome, long-term treatment with terlipressine as a bridge to liver transplantation","volume":"41","author":"Ganne-Carri\u00e9","year":"1996","journal-title":"Dig Dis Sci"},{"key":"10.1053\/jhep.2002.34343-BIB9|cit9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-8278(00)80158-0","article-title":"Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome","volume":"33","author":"Uriz","year":"2000","journal-title":"J Hepatol"},{"key":"10.1053\/jhep.2002.34343-BIB10|cit10","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00003246-199501000-00031","article-title":"Reversal of hepatorenal syndrome with the combination of norepinephrine and dopamine","volume":"23","author":"Durkin","year":"1995","journal-title":"Crit Care Med"},{"key":"10.1053\/jhep.2002.34343-BIB11|cit11","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0168-8278(98)80288-2","article-title":"Hemodynamic changes in patients developing effective hypovolemia after total paracentesis","volume":"28","author":"Vila","year":"1998","journal-title":"J Hepatol"},{"key":"10.1053\/jhep.2002.34343-BIB12|cit12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0016-5085(19)34230-1","article-title":"Effects of changing plasma volume, serum albumin concentration, and plasma osmolality on renal function in cirrhosis","volume":"53","author":"McCloy","year":"1967","journal-title":"Gastroenterology"},{"issue":"Part 2","key":"10.1053\/jhep.2002.34343-BIB13|cit13","first-page":"186A","article-title":"Effects of terlipressin administration with and without albumin in hepatorenal syndrome (HRS). A phase-II study [Abstract]","volume":"34","author":"Gines","year":"2001","journal-title":"Hepatology"},{"key":"10.1053\/jhep.2002.34343-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0140-6736(56)90149-0","article-title":"Electrolyte and circulatory changes in terminal liver failure","volume":"ii","author":"Hecker","year":"1956","journal-title":"Lancet"},{"key":"10.1053\/jhep.2002.34343-BIB15|cit15","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0168-8278(96)80297-2","article-title":"Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome","volume":"25","author":"Salo","year":"1996","journal-title":"J Hepatol"},{"key":"10.1053\/jhep.2002.34343-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1172\/JCI105224","article-title":"Prolonged infusion of angiotensin II and norepinephrine and blood pressure, electrolyte balance, and aldosterone and cortisol secretion in normal man and cirrhosis with ascites","volume":"44","author":"Ames","year":"1965","journal-title":"J Clin Invest"},{"key":"10.1053\/jhep.2002.34343-BIB17|cit17","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/hep.510280407","article-title":"Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites","volume":"28","author":"Angeli","year":"1998","journal-title":"Hepatology"},{"key":"10.1053\/jhep.2002.34343-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.510290629","article-title":"Reversal of type I hepatorenal syndrome with the administration of midodrine and octreotide","volume":"29","author":"Angeli","year":"1999","journal-title":"Hepatology"},{"key":"10.1053\/jhep.2002.34343-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/0016-5085(93)90963-D","article-title":"Impaired reactivity of peripheral vasculature to pressor agents in alcoholic cirrhosis","volume":"105","author":"Ryan","year":"1993","journal-title":"Gastroenterology"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1053%2Fjhep.2002.34343","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1053%2Fjhep.2002.34343","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200208000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T15:56:55Z","timestamp":1738943815000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200208000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,8]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002]]}},"URL":"https:\/\/doi.org\/10.1053\/jhep.2002.34343","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2002,8]]}}}